<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6050">
  <stage>Registered</stage>
  <submitdate>3/03/2016</submitdate>
  <approvaldate>3/03/2016</approvaldate>
  <nctid>NCT02713529</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer</studytitle>
    <scientifictitle>A Phase1b/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination With Pembrolizumab in Select Advanced Solid Tumors</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>MASTERKEY</secondaryid>
    <secondaryid>20150195</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pancreatic Cancer</healthcondition>
    <healthcondition>Colorectal Cancer</healthcondition>
    <healthcondition>Non-Small Cell Lung Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Pancreatic</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - AMG820 and pembrolizumab

Experimental: AMG820 and pembrolizumab - Treatment with AMG820 and pembrolizumab


Other interventions: AMG820 and pembrolizumab
Treatment with AMG820 and pembrolizumab

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of participants with treatment related adverse events as assessed by CTCAE version 4.0</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Objective response rate of tumors using irRECIST criteria for total measureable tumor burden - Analyze CT/MRI scans using a modified criteria (irRECIST) adapting the immune-related response criteria to conventional RECIST 1.1 (irRECIST accounts for index and measureable lesions in total tumor burden).</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of participants with treatment emergent adverse events as assessed by CTCAE version 4.0</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Objective response rate of tumors using RECIST 1.1 criteria for total measurable tumor burden - Analyze CT/MRI scans using defined criteria for bidimensional measurements of index lesions.</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum observed concentration [Cmax] of AMG820 - Analyze serum concentration of AMG 820 after intravenous infusion administration of AMG 820 in combination with pembrolizumab.</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>CD4, CD8, and CD68 cell numbers in pre-treatment tumor biopsy tissue</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Minimum observed concentration [Cmin] of AMG 820 - Analyze serum concentration of AMG 820 after intravenous infusion administration of AMG 820 in combination with pembrolizumab.</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area Under the Curve [AUC] of AMG820 - Analyze serum concentration of AMG 820 after intravenous infusion administration of AMG 820 in combination with pembrolizumab.</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Pathologically documented, advanced colorectal, pancreatic or non-small cell lung
             cancer that is refractory to standard treatment, or the subjects have been intolerant
             to or refuse standard treatment.

          -  Measurable disease per RECIST 1.1 guidelines.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1

          -  Adequate hematologic, renal, and hepatic function determined by laboratory blood and
             urine tests.

          -  Availability of recent tumor tissue with 3 months prior to enrollment, when feasible.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Has known active central nervous system metastases

          -  History of other malignancy with the past 2 years with some exceptions

          -  Evidence of active non-infectious pneumonitis/interstitial lung disease

          -  Evidence of other active autoimmune disease that has required prolonged systemic
             treatment in past 2 years.

          -  Evidence of clinically significant immunosuppression such as organ or stem cell
             transplantation, any severe congenital or acquired cellular and/or humoral immune
             deficiency, concurrent opportunistic infection.

          -  Receiving systemic immunostimulatory agents within 6 weeks or 5 half-lives, whichever
             is shorter, prior to first dose of study treatment (except ant PD-1/PD-L1 treatment if
             recruited into Group 4a or 4b).

          -  Evidence of active infection within 2 weeks prior to first dose of study treatment.

          -  Prior chemotherapy, radiotherapy, biological cancer therapy or major surgery within 28
             days prior to enrollment

          -  Currently participating or has participated in a study (treatment period only) of an
             investigational agent or used an investigational device within 28 days of enrollment

          -  Received live vaccine within 28 days prior to enrollment

          -  Adverse event due to cancer therapy administered more than 28 days prior to enrollment
             that has not recovered to CTCAE grade 1 or better.

          -  Positive for human immunodeficiency virus (HIV), Hepatitis B or C

          -  Women planning to become pregnant or who are lactating/breastfeeding while on study
             through 4 months after receiving the last dose of study drug.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>14/04/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>197</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>19/04/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Research Site - Camperdown</hospital>
    <hospital>Research Site - Parkville</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>3050 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Wilrijk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amgen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Merck Sharp &amp; Dohme Corp.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A multi-center Phase 1b/2 study testing the combination of AMG 820 and pembrolizumab in
      subjects with select advanced solid tumors.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02713529</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MD</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Amgen Call Center</name>
      <address />
      <phone>866-572-6436</phone>
      <fax />
      <email>medinfo@amgen.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>